 The challenge becomes that many of these new medications are also very costly. There are significant economic implications for using medications that have high costs in populations that could benefit equally, if not more, from other classes that we don't have available. This meta-analysis that we're talking about assumes that everyone was on metformin monotherapy as background, which is what we found in the trials. 80 to 90% were on metformin. So we're not talking about comparisons to metformin.